Qiagen N.V. is a global biotechnology company that specializes in providing sample and assay technologies for molecular diagnostics, pharmaceutical development, and academic research
The company develops innovative solutions that enable the extraction, purification, and analysis of nucleic acids, such as DNA and RNA, from various biological samples. Qiagen's products are designed to enhance the speed and accuracy of molecular testing, supporting the detection of diseases, genetic analysis, and the development of personalized medicine. With a strong commitment to advancing scientific research and improving healthcare outcomes, Qiagen collaborates with a range of industries and institutions to deliver reliable and efficient tools for life sciences research and clinical applications.
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer.
QIAGEN announces a comprehensive growth strategy by 2028. The plan includes significant shareholder returns, new product launches, and a focus on digital and diagnostic advancements.
U.S. stocks are looking to build on past week’s gains, with the mood remaining cautiously optimistic. The major index futures were modestly higher in early trading.
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc. (NASDAQAMZN) on Tuesday and Apple Inc.
The DAX 40 index surged to its all-time high on Tuesday, continuing the remarkable rally that started on October 23rd. The index, which tracks the 40 biggest companies in Germany, soared to a high of €16,533.
Qiagen NV's (NASDAQQGEN) Q3 net sales of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the
